Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study (Breast Cancer Research and Treatment DOI: 10.1007/s10549-007-9523-x);Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study

Breast Cancer Research and Treatment

Volumn 107, Issue 1, 2008, Pages 103-111

  Fournier, Agnès ^a   Berrino, Franco ^b   Clavel Chapelon, Françoise ^a  

^a INSERM   (France)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Cohort; Dydrogesterone; Estrogen; Hormone replacement therapy; Menopause; Progestagens; Progesterone

Indexed keywords

ANDROGEN; ANTIANDROGEN; CHLORMADINONE ACETATE; DYDROGESTERONE; ESTRIOL; ESTROGEN; GESTAGEN; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE ACETATE; PROMEGESTONE; PROMESTRIENE; TIBOLONE;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SIDE EFFECT;

EID: 36549076409     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9604-x     Document Type: Erratum

References (26)

1. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552-553
2. Stanczyk FZ (2003) All progestins are not created equal. Steroids 68:879-890
3. Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J (1998) Progestins and breast cancer. J Steroid Biochem Mol Biol 65:225-235
4. Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049-2058
5. Campagnoli C, Abba C, Ambroggio S, Peris C (2005) Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 97:441-450
6. Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647-1657
7. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059
8. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 81:339-344
9. Newcomb PA, Titus-Ernstoff L, Egan KM et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593-600
10. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
11. Stahlberg C, Pedersen AT, Lynge E et al (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721-727
12. Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130-134
13. Ewertz M, Mellemkjaer L, Poulsen AH et al (2005) Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92:1293-1297
14. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the multiethnic cohort. Int J Cancer 118:1285-1291
15. Hickey M, Davis SR, Sturdee DW (2005) Treatment of menopausal symptoms: what shall we do now? Lancet 366:409-421
16. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448-454
17. Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113-1124
18. Weiss NS, Rossing MA (1996) Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiology 7:319-322
19. Santen RJ (2003) Risk of breast cancer with progestins: critical assessment of current data. Steroids 68:953-964
20. de Lignieres B (2002) Effects of progestogens on the postmenopausal breast. Climacteric 5:229-235
21. Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502-519
22. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Mark CJ (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101:125-134
23. Muti P, Stanulla M, Micheli A et al (2000) Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes Control 11:721-730
24. Li CI (2004) Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas 49:44-50
25. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915-920
26. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95:30-37